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Objective: The aim of this study was to determine the usefulness of ozone 
therapy in the treatment of Infantile Cerebral Palsy (ICP).  
Patients and methods: A non-controlled clinical assay was made in the 
Ozone Research Center (CIO), Havana, Cuba from January 2013 to January 
2014. The sample was constituted by patients remitted to pediatrics 
consultation of CIO, to whom inclusion and exclusion criteria were applied. 
The study group involved 45 patients, from 1 month of birth to 8 years, with 
cerebral palsy of hypoxic-ischemic cause. The evaluation criteria were: 
evolution of the motor disorder according to the Gross Motor Function 
Classification System (GMFCS) scale, modification of muscle tone 
(Ashworth modified scale) and response to treatment (O’Brien modified 
scale). The way of administration was rectal insufflation; concentrations 
between 15, 20, 25 and 30 mg/L were used, volumes varied according to 
age, making calculation of the dose of ozone according to kilograms of 
weight. Cycles of 20 sessions, every 3 months were indicated, until 
completing 4 in 16 months. Patients were clinically evaluated, according to 
the scales used, before and after each cycle. 
Results and Discussion: The best answer to treatment was obtained in the 
group aged ≤ 4 years. The variables analyzed showed a significant 
improvement when the ozone treatment concluded. With respect to the 
evolution of the motor disorder, in 65 % of cases it improved. In the group of 
children below 4 years, the response was better in relation to the muscle 
tone. Response to treatment, according to the relatives’ criteria, was of 70 % 
of the children with marked improvement in the tone and muscle function. 
Conclusions: The greatest percentage of patients improved in the evolution 
of the motor disorder; when the Manual Ability Classification System (MACS) 
scale was applied, more than half the patients showed an improvement. A 
high percentage of children get a satisfactory result regarding muscle tone 
and motor function. No side effects were present in any of the cases during 
the study. 
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Infantile Cerebral Palsy (ICP) is a descriptive term historically used to group, 
with therapeutic, epidemiologic and administrative objectives, diverse motor 
and postural disorders causing limitation in the activity, attributed to non-
progressive disorders that occurred in the brain developing during fetal stage 
or early infantile stage [1, 2]. Its prevalence is between 1.5 and 3 per 1,000 
born alive. It is generally classified as congenital or acquired, according to 
the time when the brain damage occurred [3-7].
Motor syndromes are evident by alterations of posture, of voluntary 
movements and reflexes, which leads to development of a significant 
physical disability. These patients present with other alterations of 
neurodevelopment (convulsions, psychomotor and language slowness, 
disorders in learning, paying attention and conduct) in different degrees. 
Clinical manifestations vary according to age of conception, etiology and 
localization of lesions or anomalies [8)].
Pathologies associates to ICP are produced before, during or after birth all 
the same. Approximately 35% of those occurring during birth are due to 
hypoxia-ischemia (HI), but only between 12 and 23% develop moderate or 
serious ICP [9, 10]. Those neonates older than 34 weeks gestation who 
develop ICP of spastic or diskinetic quadriplegia type due to a hypoxia-
ischemic lesion during birth must present the following evidences:
1. Metabolic acidosis during birth, in the fetus or in arterial blood of the 
umbilical cord or peripheral blood at birth (pH < 7, deficit of bases > 16 
mM/L). 
2. Moderate or serious encephalopathy in the first 24 h of life.
Other factors supporting diagnosis of neonatal encephalopathy due to HI 
during birth are:
1. Presence during birth of a sentinel hypoxic event (rupture of uterus, 
detachment of placenta, prolapse of the cord, embolism of amniotic 
liquid, fetal transfusion due to previous vessels or fetal-maternal 
hemorrhage).
2. Rapid and sustained deterioration of fetal cardiac rate during the sentinel 
hypoxic event in a fetus with previous normal heart rate.
3. Apgar score from 0 to 6 for more than 5 minutes.
4. Early effect on other organs.
5. Evidences in magnetic resonance (MR) of early cerebral HI – early 
cerebral edema between 6-12 hours and, mainly, on 4 days of age in the 
majority of cases at terminus [11-14].
Infantile Cerebral Palsy (ICP) is an important health problem which 
generates great disability in childhood. There are multiple therapeutic 
alternatives [15-18], however, there is scarce available literature to support 
indication of different therapies for neurorehabilitation and that could aid 
clinical physicians in recommending them to parents.
Despite medical advances in the fields of obstetric and perinatal medicine, 
unfortunately, there is no preventive or healing treatment for ICP. Therefore, 
impossibility to avoid irreversible cerebral lesions in new born with hypoxic – 
ischemic encephalopathy and improve clinic alterations of patients with ICP 
has motivated  development of this research to evaluate the efficacy and 
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with the  patient’s Static Lesions of the central nervous system (CNS), taking 
as basis the preclinical and clinical studies carried out in diverse pathologies 
where the ischemia/reperfusion phenomenon has been present and 
beneficial results have been obtained, making possible the use of ozone, 
due to its biologic properties,  in patients with Cerebral Palsy to improve their 
quality of [19-24].
Patients and methods 
A non-controlled clinical assay was carried out in the Ozone Research 
Center (CIO) from January 2013 to January 2014.
The study was evaluated by an institutional scientific council and ethics 
committee, also follow the criteria of declaration of Helsinki.    
The sample was made up of patients referred to pediatrics consultation of 
CIO, to whom the inclusion (children between 1 month and 8 years of age 
with infantile cerebral palsy of hypoxic-ischemic cause and signed consent of 
parents to be part of the study) and exclusion criteria (infantile cerebral palsy 
of other causes, acute infectious diseases, convulsive status) were applied. 
Children between 1 month and 8 years with infantile cerebral palsy of 
hypoxic-ischemic cause remained in the study group. Their parents gave 
their signed consent being the group constituted by 45 patients.
Ozone administration was by rectal way; concentrations between 15, 20, 25 
and 30 mg/L were used, volumes varied according to the patient’s weight. 
The ozone dose was obtained multiplying a constant of 0.05 mg/kg by the 
weight in kilograms of the patient. With this ozone dose and knowing the 
ozone concentration, is it possible to calculate the ozone volume. Cycles of 
20 sessions, 5 session per week, until finish the 20 session; then were 
indicated 3 free months to completing 4 cycles in 16 months. Patients were 
evaluated clinically according to the scales used before and after each cycle. 
The analyzed variables were: 
1. Evolution of motor disorder according to the Gross Motor Function 
Classification System scale (GMFCS)
2. Evolution of patient according to the manua ability classification scale 
3. Modification of muscle tone (Ashworth modified scale) 
4. Response to treatment (O’Brien modified scale)
Evaluation criteria were the following:
For variables 1, 2 and 3
• Same: When no improvement was registered according to the scale
• Improved: Patients that showed some progress according to the 
measured scale
For variable 4
• No changes in muscle tone
• Slight improvement of muscle tone
• Slight improvement of tone and muscle function  
• Significant improvement of tone and muscle function
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Statistical analysis was made by percentage analysis, the data base was 
included and analyzed in a contingence tables, using the software, Statistical 
Package for the Social Sciences version 15.0 (SSPS).
Results 
As shown in table 1, a 71.1 % of children improved their classification in the 
Gross Motor Function Classification System scale, which demonstrates that 
they improved their motor deficit in the clinical exam, achieving a better 
score in the classification scale due to their motor deficit improvement.

In table 2 we can see how children evolved with this disorder according to 
manual abilities when carrying out the physical exam. A 46.7 % remained 
the same and 53.3% improved with respect to their manual abilities. They 
did not show significant differences related to these percentages, only a 
trend to improve. 

Analyzing table 3, we can observe that 66.7 % of the children under study 
improved muscle tone in agreement with the degree classification of 
Ashworth, clinically explored by muscle motility, strength, tone and trophy, 
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Table 1. Evolution of children with ICP according to GMFC classification.





Table 2. Evolution of children with ICP according to manual ability scale.






Table 4 shows the evolution of tone and muscle function in these children, 
taking into account the parents and physiotherapists’ criteria. There we can 
see that 46.7 % of children had a significant improvement of the tone and 
muscle function and only 11.1 % maintained without changes in this 
variable, which backs our hypothesis of evolution related to rehabilitation of 
the child with infantile cerebral palsy.

Discussion 
In Infantile Cerebral palsy we must bear in mind that brain damage is 
produced by decrease of blood flow to the encephalon affects neurons of 
different brain areas which intervene in the motor control. These are: primary 
control area of movement (Pyramidal System), movement modulation 
centers (Basal Ganglions) and the Cerebellum [25].

Damage to this group of neurons as a whole, at clinical level evidences 
diverse anomalies in motor control. It can be observed that movement is 
affected causing tremor, dyskinesia, dystonia and [25].

Encephalon has a blood flow of 45 to 55 milliliters per minute per 100 grams 
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Table 3. Evolution of children with ICP according to Ashworth scale referring to 
muscle tone.





Tabla 4. Evolution of children with ICP according to O´Brien scale referring to 
response to treatment
Criteria No. of patients %
No change 5 11.1
Slight improvement in muscle tone 3 6.7
Slight improvement in muscle tone and function 5 11.1
Significant improvement in muscle tone and function 21 46.7






grams for grey substance. This shows that metabolic activity of the brain 
tissue depends on a great extent of oxygen contribution making this tissue 
very vulnerable to hypoxia [25,26].

In our study, patients included proved a diagnosis of Infantile Cerebral Palsy 
of Hypoxic-Ischemic cause. For the result analysis, we must take into 
account some aspects of physiopathology of cerebral ischemia. For 
example, during cerebral ischemia, production of adenosine triphosphate 
(ATP) is reduced affecting the activity of Calcium ATP-ase enzyme. As a 
result, there is an abnormal increase of concentrations of this ion within the 
neuron leading to the release of excitatory neurotransmitters, such as 
glutamate (greatly responsible for excitotoxicity phenomena), release of free 
radicals in the ischemic cerebral tissue and inhibition of ATP production [27]. 
It is known that during cerebral ischemia there is production of abnormal 
high concentrations of reactive oxygen species (ROS), among which are the 
superoxide anion (O2.-), the hydroxyl  radical (OH-), nitric oxide (NO) and 
peroxynitrite anion (ONOO-); all of them involved in neurodamage occurring 
during ischemia [27,28]. Also, in cerebral ischemia there is overstimulation 
of phospholipase A2, responsible of increase of degradation products of 
membrane phospholipids. These products accumulate and can turn into a 
platelet activating factor with an enhancement effect of platelet aggregation 
and inducer of inflammatory response by means of leukocytes adhesion 
and aggregation, hindering the passage of the blood flow to the encephalon 
[28].

In addition, during decrease of cerebral blood flow an inflammatory gene 
expression is induced in different types of cells causing release of pro-
inflammatory cytokines [27-28]. Interleukin 1-β (IL-β) and tumor necrosis 
factor α (TNF-α) are the cytokines that start the inflammatory response and 
interleukin 6 (IL-6) is the one that mediates the late inflammatory response 
in ischemic cerebral tissue [29]. IL-6 and TNF-α stimulate production of 
metalloproteinase, specifically the MMP-9. This metalloproteinase is 
responsible for alteration of the blood-brain barrier conditioning the 
occurrence of vascular edema and contributing to hemorrhagic 
transformation of infarct [29].

Beginning with the interpretation of the results obtained, for quantitative 
description of the motor function, in our study we used the GMFCS 
classification system, a tool that determines the degree of motor function 
limitation of patients with ICP [30,31].

With respect to distribution at encephalic level of some antioxidants, it is 
known that vitamin E concentration in the cerebellum is low. On the other 
hand, it has been demonstrated that antioxidant enzymes like catalase have 
a lower concentration in the brain in relation to other tissues.

The most studied excitotoxin is glutamate. In physiologic conditions it is an 
excitatory neurotransmitter. However, excessive levels turn out to be toxic 
and determine the death of retinal ganglion cells [30]. The term 
excitotoxicity is stamped to describe this effect (Exciter + toxic = Excito-
toxin) [31].

A high local concentration of glutamate stimulates receptors of the cell 
surface, mainly the N-methyl-D-aspartate (NMDA), which opens the calcium 
channels, determining an intracellular overcharge of this ion with the 
subsequent activation of the nitric oxide synthase enzyme, which generates 
the nitric oxide with free radical properties. Glutamate, as well as nitric 
oxide, are neurotransmitters in normal conditions. However, when NMDA 
receptors are hyper stimulated, the nitric oxide combines with reactive 
mediators to oxygen generating peroxynitrates that produce nitrosylation 
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With respect to spasticity, bulbar reticular formation inhibits the muscle 
tone, the inhibitory bulboreticular region receives orders from the motor 
cortex, anterior lobule of cerebellum and the basal ganglions. The exciter 
way of muscle tone is the medial reticule spinal fascicle from the bridge, 
that is, from reticular formation of the bridge.

There must be a balance between the excitatory and inhibitory ways of the 
muscle tone. For example, a lesion in the cortical-bulbar fibers at cortex 
level, or in an internal capsule it reduces inhibition of the muscle tone, in 
which a supremacy of the excitatory ways is produced with occurrence of 
spasticity [28-30,33].

Ozone oxidative pre/post-conditioning is an ozone’s mechanism of action 
which has been demonstrated from experimental and clinical point of view 
[34-45]. Ozone therapy promotes a slight and transient oxidative stress 
through its capacity to ¨trigger¨ antioxidant endogenous system in order to 
re-establish antioxidant/pro-oxidant balance preserving mitochondrial 
integrity and superoxide dismutase activities [37,39]. Ozone is able to re-
established the cellular redox balance with a significant reduction in 
oxidative stress, which is one of the main processes unleashing the 
pathological cascade that induces protein injury in cerebral palsy of 
hypoxic-ischemic cause. On the other hand, the decrease in phospholipase 
A2 (PLA2) activity after ozone treatment suggests the reduction in 
inflammatory mediators produced in the arachidonic acid cascade [19,20, 
22,23]. Ozone protected against protein damage through regulation of ROS, 
preserving mitochondrial integrity and functionality [37,42].  Moreover, in 
experimental models studied, levels of nitric oxide, pro inflammatory 
cytokines, like the tumor necrosis factor (TNF- α) and interleukin 1 and 6, 
protease calcium-dependent activity, as well as overexpression of nuclear 
factor-kappa-B activity, were able to be modulated by ozone treatment 
[36,38-40,43]. Another aspect to be taken in consideration is the role of 
ozone in activating A1 adenosine receptors [21]. Adenosine, acting on 
presynaptic A1 receptors, is able to inhibit glutamate release at excitatory 
synapses and, thus counteracts the neuronal hyper excitability that occurs 
during cerebral ischemia and spasticity [1,46-48]. Ozone´s beneficial effects 
suggest that ozone is able to achieve a balance between γ-aminobutyric 
acid (GABA), the primary inhibitory neurotransmitter, and glutamate, the 
major excitatory neurotransmitter [49,50].

All these physiopathologic mechanisms associated to infantile cerebral 
palsy of hypoxic-ischemic cause explain the positive results in our patients 
after the ozone treatment mainly based on its effect, a stimulant of the 
antioxidant defense system of the organism, improving the oxygen 
contribution to the brain tissue and to the rest of the body by increasing the 
blood flow and acting as a neuroprotective agent.

Conclusions 
It was observed that the highest percentage of patients improved in the 
evolution of motor disorder according to the Gross Motor Function 
Classification scale. At applying the Manual Ability Classification System 
(MACS) scale, more than half the patients evidenced an improvement. On 
the other hand, the highest percentage of patients showed a significant 
improvement in muscle tone and motor function. No side effects were 
observed during the study. We recommend the application of Ozone therapy 
in the rehabilitation of children with cerebral palsy of hypoxic-ischemic 
cause and also in order to encouraging the results of this study support 
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